SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

1 marketing jobs

Guardant Health logo
2 weeks ago

Director, Performance & Digital Marketing

Guardant Health

Palo Alto, CA (Hybrid)Full time$166K/yr – $268K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Guardant Health logo

Director, Performance & Digital Marketing

Guardant Health

Palo Alto, CA (Hybrid)

$166K/yr - $268K/yrIn-houseFull-timeDirector/executive15+ years exp.
2 weeks ago
Guardant Health logo
Guardant Health

Director, Performance & Digital Marketing

Palo Alto, CA (Hybrid)

$166K/yr – $268K/yrDirector/Executive15+ years expFull time

Posted 2 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the strategy and performance of Shield’s multi-channel DTC media plan, overseeing national media strategy, investment allocation, measurement, and executive reviews across Consumer Marketing, HCP, and Health Systems contexts.

  • Own media strategy and budget stewardship
  • Coordinate cross-functional planning with Analytics, Finance, and Marketing

Job Description

Responsibilities

  • Own the strategy, deployment, optimization, and performance of Shield’s significant multi-million-dollar DTC media investment, one of the most important growth investments within the Shield business.
  • Set the national consumer media strategy across television, streaming, online video, search, social, programmatic, audio, local media, and emerging channels.
  • Determine investment levels, channel allocation, audience strategy, geographic prioritization, flighting, reach, frequency, and optimization approaches.
  • Balance long-term brand building with near-term demand generation and measurable patient action.
  • Partner with Consumer Marketing leadership to translate brand and audience strategy into an integrated media plan that builds awareness, creates urgency, and motivates patients to ask for Shield by name.
  • Advise the Vice President of Marketing and senior commercial leadership on major investment decisions, trade-offs, risks, and opportunities.
  • Lead executive-level reviews of DTC performance, clearly articulating what is working, what is not, and where investment should be increased, redirected, or reduced.
  • Ensure rigorous budget stewardship, including forecasting, pacing, agency fees, production implications, working versus non-working spend, and financial reconciliation.
  • Build a measurement framework that connects DTC investment to awareness, consideration, site engagement, patient action, provider demand, test orders, and incremental business impact.
  • Establish a disciplined testing agenda across audiences, creative, messaging, channels, media weight, sequencing, and geographic markets.

Requirements

  • Bachelor’s degree in Marketing, Business, Communications, Analytics, or a related field; advanced degree preferred.
  • 15+ years of progressive experience in media, performance marketing, digital marketing, or integrated marketing, including significant leadership responsibility.
  • Demonstrated success managing significant multi-million-dollar media budgets or advertising portfolios with accountability for strategy, allocation, optimization, and performance.
  • Experience leading complex national or multi-channel media programs across brand and performance objectives.
  • Deep expertise across television, streaming, programmatic, search, social, endemic HCP media, account-based marketing, CRM, web, SEO, conversion optimization, and marketing automation.
  • Proven ability to build integrated strategies across brand building, demand generation, customer engagement, and commercial activation.
  • Strong agency leadership experience, including agency selection, contract and scope management, governance, and performance accountability.
  • Advanced understanding of media measurement, attribution, experimentation, audience strategy, and marketing analytics.
  • Experience defining or advancing marketing technology, customer data, personalization, and AI-enabled marketing capabilities.
  • Demonstrated ability to influence executives and lead across a complex, highly matrixed organization.
Guardant Health logo

Guardant Health

3.2 Glassdoor

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, we're transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.Important Note for Job Applicants:Guardant Health is aware of recruiting scams where unauthorized individuals use the company's name in fraudulent emails, job postings, and social media messages. Please note that Guardant Health will never ask for money or credit card information during the job application process, nor does the company communicate with candidates via online chatrooms or personal email accounts such as Gmail or Hotmail.

Founded in 2012
Palo Alto, California, USA
4K employees (169 in marketing)
guardanthealth.com
53% recommend to a friend
65% CEO approval

Salaries

Posted range

$166K/yr – $268K/yr

Taken straight from the job posting.

See all Guardant Health salaries

Marketing Team

Marketing Team Size
110 (3% of company)
Median Career Experience
14 years
Median Tenure
4.1 years
Marketing Roles Posted (Last 30 Days)
1

People

Marketing Leadership

Lindsey K.
Lindsey K.
VP of Marketing
At the company for 1 year 4 months
James Chapman
James Chapman
Vice President Marketing, Oncology
At the company for 5 years 1 month
Stephen Murphy
Stephen Murphy
Head of Marketing
At the company for 2 years 10 months
Tina Wang
Tina Wang
Associate Director Product Marketing
At the company for 1 year 2 months

Funding

Total Funding
$2.5B
Last Raise
$284.4M
Post IPO Debt, 4 months ago

Funding History

  • Nov 2025
    Post IPO Equity • $284.4M
  • Nov 2025
    Post IPO Debt • $350M
  • Dec 2023
    Post IPO Equity • $90.7M

Traffic Signals

Monthly Visitors
50.6K
Monthly Google Ads Budget
$42.8K
Traffic Source Mix
Search
36.3%
Direct
53.6%
Referral
7.2%
Social
1.3%
Paid
0.8%

Headcount Trend

Current headcount: ~4K

Recent News

Is Guardant Health's (GH) Push for Open Data Standards Reshaping Its Sector Leadership and Growth Prospects?
Nov 16, 2025 • Yahoo Finance
Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access
Nov 12, 2025 • Yahoo Finance
Guardant blood test gives early warning of cancer progression in chemo patients, study finds
Nov 10, 2025 • Fierce Biotech
Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring
Nov 10, 2025 • Yahoo Finance
Guardant Health (GH): Assessing Valuation Following Expanded Equity and Convertible Capital Raises
Nov 8, 2025 • Yahoo Finance
Guardant Health prices upsized $300 million common stock offering
Nov 5, 2025 • Investing.com
Why Guardant Health (GH) Shares Are Sliding Today
Nov 5, 2025 • Yahoo Finance
Guardant Health Announces Proposed Public Offering of Common Stock
Nov 4, 2025 • Yahoo Finance
Guardant Health (GH) Jumps to New Record High on Earnings Blowout, Bullish Outlook
Oct 31, 2025 • Yahoo Finance
Why Guardant Health Was Such an Investor Darling This Week
Oct 31, 2025 • The Motley Fool
Guardant Health (GH): Revenue Growth Outpaces Market, Profitability Challenges Reinforce Bearish Narratives
Oct 30, 2025 • Yahoo Finance
Guardant Health Stock Soars 21% After-Hours As Strong Q3, Raised Guidance Spark Retail Frenzy
Oct 30, 2025 • Stocktwits
Guardant Health Stock Soars On Strong Q3 Results, Upbeat FY 2025 Outlook
Oct 30, 2025 • Nasdaq
Why Guardant Health Stock Surged Today
Oct 30, 2025 • The Motley Fool
Why IBD 50's Guardant Health, Up 137% in 2025, Just Rocketed Again
Oct 30, 2025 • Investor's Business Daily
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Oct 29, 2025 • Yahoo Finance
Guardant Health partners with Zephyr AI to advance cancer research
Oct 27, 2025 • MobiHealthNews
Earnings To Watch: Guardant Health (GH) Reports Q3 Results Tomorrow
Oct 27, 2025 • Yahoo Finance
Guardant Health (GH) Is Up 7.9% After FDA Approval of Blood Test for Lilly’s Inluriyo
Oct 22, 2025 • Yahoo Finance
Stock Of The Day: Why IBD 50's Guardant Health Has Rallied 31% In A Month
Oct 20, 2025 • Investor's Business Daily
A Fresh Look at Guardant Health (GH) Valuation Following Recent Share Price Rally
Oct 18, 2025 • Yahoo Finance
Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025
Oct 15, 2025 • Yahoo Finance
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025
Oct 9, 2025 • Yahoo Finance
How FDA Approval of Guardant360 CDx as Companion Diagnostic Could Impact Guardant Health (GH) Investors
Oct 3, 2025 • Yahoo Finance
Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy
Sep 30, 2025 • Yahoo Finance
FDA OKs Guardant Health companion diagnostic for Lilly's breast cancer drug
Sep 29, 2025 • FirstWord Pharma
Why Guardant Health (GH) Stock Is Trading Up Today
Sep 29, 2025 • Yahoo Finance
Guardant’s New Blood Test Can Detect Many Different Cancers. The Company Is Promising the Same for Other Diseases.
Sep 26, 2025 • Barron's
In Brief This Week: Quest Diagnostics, Guardant Health, Illumina, Pictor, MyHealthChecked
Sep 26, 2025 • GenomeWeb
Guardant’s New Blood Test Can Detect Many Different Cancers. The Company Is Promising the Same for Other Diseases.
Sep 26, 2025 • Yahoo Finance
Guardant Health price target raised by $10 at Canaccord, here's why
Sep 26, 2025 • thefly.com
Quest to distribute Guardant colon cancer blood test
Sep 25, 2025 • MedTech Dive
Guardant Health (GH) Stock Trades Up, Here Is Why
Sep 25, 2025 • Yahoo Finance
Wolfe Research lifts Guardant Health to Outperform, sees 30% upside
Sep 25, 2025 • Investing.com
Guardant Health price target raised by $10 at Stifel, here's why
Sep 25, 2025 • thefly.com
Wolfe Research gets more bullish on Guardant Health, upgrades shares
Sep 25, 2025 • thefly.com
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
Sep 25, 2025 • BioSpace
Wolfe upgrades Guardant to Outperform after 'solid' analyst day
Sep 25, 2025 • thefly.com
Guardant Health price target raised by $10 at JPMorgan, here's why
Sep 25, 2025 • thefly.com
Guardant Health price target raised by $10 at UBS, here's why
Sep 25, 2025 • thefly.com
Guardant Health price target raised by $5 at Mizuho, here's why
Sep 25, 2025 • thefly.com
Guardant Health rises 7.9%
Sep 25, 2025 • thefly.com
Guardant Health price target raised by $9 at TD Cowen, here's why
Sep 25, 2025 • thefly.com
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
Sep 24, 2025 • Yahoo Finance
What Catalysts Are Changing the Narrative for Guardant Health?
Sep 24, 2025 • simplywall.st
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
Sep 24, 2025 • MarketScreener
Guardant Health, Quest Diagnostics announce blood-based screening test pact
Sep 24, 2025 • thefly.com
People Diagnosed with Lung Cancer Aren't Getting Vital Tests; New Campaign Hopes to Change That
Sep 24, 2025 • PR Newswire
People Diagnosed with Lung Cancer Aren't Getting Vital Tests; New Campaign Hopes to Change That
Sep 24, 2025 • Morningstar.com
Transcript : Guardant Health, Inc. - Analyst/Investor Day
Sep 24, 2025 • MarketScreener
UPC sees next life sciences case as Guardant sues Sophia Genetics
Sep 23, 2025 • JUVE Patent
Guardant Health (GH) Stock Is Up, What You Need To Know
Sep 23, 2025 • Yahoo Finance
The rise of genomic copilots in drug development
Sep 23, 2025 • Pharma Letter
U.S. Oncology Molecular Diagnostics Market to Capture USD 2570.17 Mn by 2034
Sep 23, 2025 • Precedence Research
Guardant Health initiated with bullish view at Wells Fargo, here's why
Sep 22, 2025 • thefly.com
Exact Sciences scares up spooky season Cologuard campaign starring Matthew Lillard
Sep 22, 2025 • FiercePharma
People in the News at Guardant Health, Personalis, GeneDx, Cedars-Sinai, Lucid Diagnostics
Sep 19, 2025 • GenomeWeb
Testing & Diagnostics Services Q2 Earnings: Guardant Health (NASDAQ:GH) is the Best in the Biz
Sep 18, 2025 • Yahoo Finance
Guardant Health (GH) director Potter sells $1446 in stock
Sep 17, 2025 • Investing.com
Q2 Earnings Recap: Guardant Health (NASDAQ:GH) Tops Testing & Diagnostics Services Stocks
Sep 17, 2025 • Yahoo Finance
Alex M. Azar II Joins Guardant Health Board of Directors
Sep 15, 2025 • Yahoo Finance
Alex M. Azar II Joins Guardant Health Board of Directors
Sep 15, 2025 • Business Wire
Alex M. Azar II joins Guardant Health board of directors
Sep 15, 2025 • MarketScreener
Alex M. Azar Ii Joins Guardant Health Board Of Directors
Sep 15, 2025 • Reuters
Have Insiders Sold Guardant Health Shares Recently?
Sep 14, 2025 • simplywall.st
Blood Testing Market to Reach USD 249.7 Billion by 2035, Growing at 8.2% CAGR from USD 104.4 Billion in 2024 | TMR
Sep 12, 2025 • EIN Presswire
Demand for Genetic Mutation Analysis Market is forecasted to reach a value of US $10.3 billion by 2029
Sep 12, 2025 • EIN Presswire
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership
Sep 11, 2025 • Morningstar.com
Guardant Health Partners With LabFlorida to Offer Shield CRC Screening Test to Senior Communities
Sep 11, 2025 • GenomeWeb
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
Sep 8, 2025 • Yahoo Finance
Guardant Health, PathGroup Partner to Bring Shield Blood Test to 250+ Hospitals Across 25 States
Sep 8, 2025 • Reuters
Liquid Biopsy Market to Reach USD 30.65 Billion by 2035, with CAGR 9.41% Driven by Rising Cancer Burden and Demand for Non-Invasive Diagnostics - Vantage Market Research
Sep 8, 2025 • PR Newswire UK
Guardant Health, PathGroup partner to bring Shield blood test to 250+ hospitals across 25 states
Sep 8, 2025 • MarketScreener
Guardant Health, PathGroup Ink Deal to Accelerate Commercial Distribution of Shield CRC Test
Sep 8, 2025 • GenomeWeb
Guardant Health reports positive clinical readout update for Shield algorithm
Sep 5, 2025 • Medical Device Network
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test
Sep 4, 2025 • Yahoo Finance
Guardant Health stock decline after data a 'bit' overdone, says Raymond James
Sep 4, 2025 • thefly.com
Guardant Health falls -8.3%
Sep 4, 2025 • thefly.com
Why IBD 50's Guardant Health Just Tumbled, Breaking A 67% Monthlong Run
Sep 4, 2025 • Investor's Business Daily
Noninvasive Cancer Diagnostics Market to Hit USD 255.25 Billion by 2033 | 9.9% CAGR Driven by Liquid Biopsy
Sep 2, 2025 • EIN Presswire
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • PR Newswire UK
Global Cancer Diagnostics Market to Hit USD 215 Billion by 2035, Growing at 6.35% CAGR | Vantage Market Research
Sep 2, 2025 • PR Newswire UK
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • Canada NewsWire
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
Sep 2, 2025 • PR Newswire
Guardant Health’s Earnings Boost Prospects
Aug 29, 2025 • StocksToTrade
Guardant Health to Host Investor Day on September 24, 2025
Aug 28, 2025 • Yahoo Finance
Guardant Health to Host Investor Day on September 24, 2025
Aug 28, 2025 • Business Wire
Guardant Health stock hits 52-week high at 64.74 USD
Aug 28, 2025 • Investing.com
Cancer Diagnostics Market to Grow at a CAGR of 9.4% from 2025 to 2032 | SkyQuest Technology Consulting
Aug 28, 2025 • PR Newswire
Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 26, 2025 • Yahoo Finance
Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 26, 2025 • BioSpace
Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™
Aug 22, 2025 • MarketsandMarkets Research Pvt. Ltd.
Clinical Diagnostics Market Outlook Report 2025-2030 | Agile Investment in AI and Emerging Markets Key to Sustained Growth in Diagnostics - ResearchAndMarkets.com
Aug 22, 2025 • Business Wire
Guardant Health stock hits 52-week high at 60.69 USD
Aug 21, 2025 • Investing.com
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 15, 2025 • Yahoo Finance
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 15, 2025 • Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 15, 2025 • MarketScreener
Guardant Health announces inducement grants under Nasdaq Listing Rule
Aug 15, 2025 • MarketScreener
Guardant Health at Canaccord Conference: Strategic Growth Unveiled
Aug 13, 2025 • Investing.com
The 5 Most Interesting Analyst Questions From Guardant Health’s Q2 Earnings Call
Aug 12, 2025 • Yahoo Finance

Links

guardanthealth.comLinkedInX (Twitter)Crunchbase